

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Sixth Wave Innovations Inc. (the "Issuer").

Trading Symbol: SIXW

Number of Outstanding Listed Securities: 117,307,988

Date: September 7, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On August 3, 2021, the Issuer announced that its molecular detection technology has successfully detected the Delta variant of the SARS-CoV-2 virus that causes COVID-19. Detection was accomplished through a colour-based sensor that uses the Issuer's patent-pending Accelerated Molecular Imprinted Polymers

("AMIPs™") technology. The test work was performed under the direction of Dr. Michael Joyce, a senior research scientist in medical microbiology at the University of Alberta's Li Ka Shing Institute of Virology.

The Issuer's work has clearly demonstrated the ability to create a molecular imprinted polymer for additional viruses and bacteria, demonstrating that the AMIPS market extends well beyond clinical testing and COVID-19. The Issuer is quickly moving through a program of development and scale-up milestones toward a wide range of AMIPs Virus rapid detection devices. The spectrum of prospective products will include the Issuer's ER's SmartMask™ offerings, in addition to smart-clothing, PPE applications, airborne sensors, breathalyzers, ELISA-based technologies, cartridge/lateral flow designs, and others.

The colour-based sensor testing using a pseudo-ELISA test format demonstrated functionality similar to an enzyme-linked immunosorbent assay ("ELISA") test) and was achieved using a commercial off-the shelf fluorescent dye. The virus samples were tested in cell culture supernatant to allow for basic specificity parameters. The fluorescent-based sensors demonstrated a significant signal compared to the negative control (cell culture supernatant without virus).

The results of this work align closely with research being performed by the Issuer and York University toward the development of additional sensor formats using AMIPS. Several techniques for creating novel sensor arrays using AMIPS have shown high sensitivity and are applicable for detecting biological material in both air and liquid samples.

On August 5, 2021, the Issuer announced the finalization of a commercial system design for Affinity™ cannabis purification technology. The Issuer is contracted to deliver three units to Oregon-based producer Green Envy Extracts after successful field trials beginning in the fall of 2021.

The Affinity™ System is a leading-edge purification process that will allow cannabis producers to deliver a product with the highest possible THC/cannabinoid purity with greater consistency that consumers demand. Affinity™ machines will use the Issuer's nanotechnology to significantly increase yields for producers by reducing the amount of cannabis lost through traditional methods in faster times with lower costs.

The Issuer continues to regularly receive new inquiries on the availability of the Affinity™ System and the Issuer plans to convert these opportunities into hard sale orders in the coming months.

Bench-scale testing has already indicated that Affinity is capable of superior adsorption kinetics for THC over the CBD extracted from hemp. Final configuration work is aimed toward optimization of standard operating procedures for cannabis extracts.

Recent improvements in the polymer beads and optimizing procedures indicate that Affinity will achieve the goal of enabling entry-sized machines to process 20kg of finished distillate per day. The Issuer envisions potential revenue generation in excess of \$1.25M annually from each machine when used at capacity while providing the licensed producer the opportunity to capture between 20-40% more cannabinoids from the crude extract and with a higher quality product adding directly to their bottom line.

Ongoing work includes:

1. Validation and/or update to the crude extract preparation Standard Operating Procedure for possible changes to accommodate this specific type of extract material. The Affinity system allows us to remove the winterization process and replace it with sample preparation that does not require cryogenic refrigeration and is much faster than winterization. This is accomplished in a single process that also dilutes the crude extract so that it flows through the Affinity columns for isolation of the cannabinoids.
2. Selection of final Affinity bead design for product rollout. The Issuer has currently completed extensive design, manufacture, testing, and initial scale-up work on four high-performance formulations. Several designs have exceeded initial expectations and functional design specifications. The beads show performance advantages on several key parameters that reduce operating costs, reduce ethanol usage, and improve capacity. Final evaluation of purity level designs associated with hemp and cannabis crude is ongoing to optimize performance. The work is on schedule for Green Envy delivery and bead production scale-up.

On August 11, 2021, The Issuer announced a signed amendment to the research agreement and grant sponsored by the Natural Sciences and Engineering Research Council of Canada titled: Point-of-need Microfluidic Biosensor for Detecting Airborne Viruses using Molecularly Imprinted Polymers: Towards COVID-19 Virus Monitoring. The goal of the grant is to develop a portable, low-cost technology for rapid on-site air sampling and detection of aerosol and droplet-encapsulated viruses indoors and outdoors. The project is a collaboration between the Issuer and its partners, York University ("York") and the Centre Technologique des Residus Industriels ("CTRI"). The project had a start date of August 1, 2020. Work to date has focused on designing a prototype(s) of the Issuer's AMIP technology to detect pathogens in airborne, water, and wastewater environments. The collaboration is part of the Issuer's multi-pronged R&D approach to revolutionize virus detection by being able to test individual patients as well as monitoring entire populations through proactive measures such as pathogen detection in a variety (buildings, ships, aircraft, etc.) of air handling systems (HVAC) and municipal wastewater treatment facilities.

The collaboration with York and CTRI has yielded new configurations and potential applications for the AMIP technology. Research conducted at York has demonstrated several of the previously disclosed potential capabilities of AMIP technology. Specifically, the integration of the technology into a variety of sensor arrays and detection mechanisms including electrochemical and fluorescent-based sensors. The work has also demonstrated the ability to detect a variety of pathogens, including viruses and bacteria.

Microfluid devices or lab-on-a-chip devices are promising platforms to achieve rapid and sensitive immunological detection of pathogenic microorganisms such as bacteria and viruses. Inside these submicroliter reactors, sample and reagent consumption can be significantly reduced, and the reaction time for target immobilization and identification can be shortened from hours to minutes or less. The Issuer's AMIPs technology allows for novel product configuration not possible with traditional testing techniques. As a result, AMIPs has greater stability and

significantly less susceptibility to environmental variables such as heat, light, and other factors which may impact traditional testing methods.

The Issuer is not making any express or implied claims that its product has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time.

On August 16, 2021, the Issuer announced the signing of a contract which provides for the continuation of testing of the Issuer's patented IXOS® purification polymer at Rio2's Fenix Gold Project in Chile using Rio2's nearby Lince Infrastructure facilities. The contract follows the successful completion of testing done on representative samples of ore from Rio2's Fenix Gold Project at the Issuer's Salt Lake City, Utah facility undertaken pursuant to the non-binding Letter of Intent entered into between the Issuer and Rio2 in September 2020. The move to near-site testing represents a significant step forward, and investment by the two companies in the trial test project.

Under the terms of the LOI, Rio2 sent representative ore samples from its Fenix Gold Project to the Issuer for testing and analysis. The testing confirmed that IXOS® Mining Technology outperformed activated carbon on several key metrics including gold adsorption efficiency, ease of elution, and overall adsorption kinetics. A comprehensive costs/benefit analysis was performed using the data obtained in the laboratory testing along with ongoing testing performed by Rio2 on activated carbon as part of their pilot operations. The analysis also detailed the expected plant size, potential CAPEX and OPEX savings, and expansion capability/pathways. IXOS® polymer is reusable and the potential for favorable usage life over activated carbon especially with scaling agents in the mine's water source provided sufficient encouragement that the project should proceed to the next phase of test work. Sixth Wave will perform recovery tests from leach solution using its IXOS® Mining Technology and the leaching columns already commissioned and utilized by Rio2 to evaluate adsorption kinetics and other parameters. Testing is expected to start in Q4 2021, post-winter months, assuming that current COVID-19 restrictions in Chile will abate. The testing will include 50 days of on-site operation of the system under a variety of testing scenarios to validate IXOS® performance and determine additional details regarding the cost/benefit analysis. Tests with a parallel set of activated carbon columns will allow for direct comparison between the two adsorbents under common testing conditions. The potential positive environmental impact and reduced carbon footprint (CO2 emissions) of using IXOS® over activated carbon for the process plant will also be explored during this phase of the project.

Consistent with the terms of the LOI, Rio2 will pay travel expenses, external test work, and the operation of the pilot equipment during the test. The Issuer's team will be lead by Mr. Nicol Newton, Director of Technical Services and a 20 year gold mining veteran. Mr. Newton will be accompanied by Dr. Glen Southard, one of the inventors and developers of IXOS® Mining Technology. The Issuer will provide in-kind labor to support testing and analysis and all of the testing apparatus/pilot equipment for use during the project. The field kit will be returned to the Issuer upon completion of the pilot. Upon successful completion and receipt of positive results from the column test pilot program, the companies will move to a second

near site testing phase incorporating the IXOS® Mining Technology into a long term pilot plant that will operate alongside the currently planned carbon adsorption circuit. This will provide long-term operational data including the determination of the useful life of the IXOS® polymer beads, and specifications for full-scale implementation pegged to the mine operation and potential future mine expansion plans.

On August 19, 2021, the Issuer announced that it has improved the sensitivity and capability of its leading-edge nanotechnology to detect the presence of the SARS-CoV-2 at levels below 1,000,000 virus particles/mL. This high level of sensitivity is crucial to detecting infectious patients, and an important clinical weapon in the struggle to control the global spread of the Covid pandemic.

Testing at the La Ki Shing Institute was carried out using live SARS-CoV-2 virus and Issuer's fluorescent based pseudo-ELISA in their BSL 3 certified facilities. The pseudo-ELISA test uses the Issuer's patent pending Accelerated Molecular Imprinted Polymers technology.

In the research at Li Ka Shing, the samples were tested in cell culture supernatant to allow for basic specificity parameters. The fluorescent-based sensors demonstrated significant signal compared to the negative control (cell culture supernatant without virus). The colour-based sensor testing using a pseudoELISA test format (pseudo-ELISA - demonstrated functionality similar to an enzyme-linked immunosorbent assay test, and was achieved using a commercial off-the-shelf fluorescent dye.

The Issuer has filed two patents regarding the AMIPs™ technology and its application to specific products that can utilize AMIPs™. The Issuer is not making any express or implied claims that its current AMIPs™ product has the ability to eliminate, cure, contain, or detect, at a commercial level, COVID-19 (or SARS-2 coronavirus) at this time.

2. Provide a general overview and discussion of the activities of management.
See section 1.
3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.
Not applicable
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.
Not applicable.
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See section 1.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

Not applicable.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

On August 3, 2021, the Issuer issued 100,000 common shares to settle DSU's.

Security	Number Issued	Details of Issuance	Use of Proceeds
----------	---------------	---------------------	-----------------

Common Shares	100,000	The Issuer has issued 100,000 common shares as a result DSU's settled during the period.	N/A
---------------	---------	--	-----

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers or committee members.

Not applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are outlined in the Issuer's interim Financial Statements and Management Discussion and Analysis for the period ended May 31, 2021. The Financial Statements and Management Discussion and Analysis are available on the Issuer's SEDAR profile at www.sedar.com and on the Issuer's disclosure with the CSE at www.thecse.com

In addition to the trends and risks outlined in the Issuer's Management Discussion and Analysis COVID-19 may impact the Issuer as noted below:

The Issuer may face disruption to operations, supply chain delays, travel and trade restrictions and impact on economic activity in affected countries or regions can be expected and can be difficult to quantify. Such pandemics or diseases could represent a threat to maintaining a skilled workforce industry and could be a health-care challenge to the Issuer. There can be no assurance that the Issuer's personnel will not be impacted by these pandemic diseases and ultimately that the Issuer would see its workforce productivity reduced or incur increased medical costs/insurance premiums as a result of these health risks. In addition, the COVID-19 pandemic has created a slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, Government response actions, business closures, and business disruptions, can all have an impact on the Issuer's operations and access to capital. There can be no assurance that the Issuer will not be impact by adverse consequences that be brought about by the COVID-19 pandemic on global financial markets.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated September 8, 2021.

Peter Manuel
Name of Director or Senior
Officer

/S/ Peter Manuel
Signature
CFO
Official Capacity

Issuer Details Name of Issuer Sixth Wave Innovations Inc.	For Month End: August 2021	Date of Report YY/MM/D 21/09/07
Issuer Address Suite 830-1100 Melville Street		
City/Province/Postal Code Vancouver, BC, V6E 4A6	Issuer Fax No. (902) 492-0197	Issuer Telephone No. 902-835-0403
Contact Name Peter Manuel	Contact Position CFO	Contact Telephone No 902-835-0403
Contact Email Address peter@sixthwave.com	Web Site Address www.sixthwave.com	